Expert Oncology Update: New Immunotherapy Combinations Reshaping First-Line Lung Cancer Care

Recent Trends in First-Line Immunotherapy Combinations

Over the past several quarters, the treatment landscape for advanced non-small cell lung cancer (NSCLC) has shifted notably toward multi-agent immunotherapy regimens. Regimens pairing PD-1 or PD-L1 inhibitors with CTLA-4 blockade, with TIGIT inhibitors, or with chemotherapy are now being adopted earlier in the disease course. Regulatory approvals and updated clinical guidelines have accelerated this shift, with combination strategies increasingly preferred over single-agent checkpoint inhibitors, particularly for patients with non-squamous histology and lower PD-L1 expression.

• PD-1/PD-L1 + CTLA-4 inhibitor combinations are showing durable survival benefits in certain subgroups.
• TIGIT-targeting agents combined with anti–PD-L1 have demonstrated improved progression-free survival in early-phase data.
• Chemo-immunotherapy continues to be a backbone for patients with no contraindications to platinum doublets.

Background: Why Combination Approaches Are Gaining Momentum

For years, first-line treatment for advanced NSCLC was dominated by platinum-based chemotherapy or, for high PD-L1 expressers, single-agent checkpoint inhibitors. While single-agent immunotherapy offered durable responses for some, many patients either did not respond or experienced early progression. Combinations aim to overcome resistance mechanisms — for example, by engaging multiple immune checkpoints or by priming the tumor microenvironment through chemotherapy-driven antigen release. This rationale has driven a wave of clinical trials testing various synergistic pairings.

Key clinical consideration: Patient selection remains critical. Not all combinations are suitable for all histologies, and biomarkers beyond PD-L1 (such as tumor mutational burden, gene signatures, or microsatellite stability) are being integrated to refine choices.

User Concerns: Balancing Efficacy, Toxicity, and Practicality

Oncologists and patients face several trade-offs when selecting first-line immunotherapy combinations. Common concerns include:

• Increased toxicity: Dual checkpoint blockade can raise rates of immune-related adverse events (irAEs) — particularly colitis, pneumonitis, and hepatitis — compared to single agent therapy. Close monitoring and early intervention protocols are essential.
• Cost and access: Multidrug regimens typically carry higher upfront costs, and insurance coverage may vary by region and indication. Real-world data on long-term financial burden are still maturing.
• Treatment duration: Optimal duration of combination therapy — especially after a period of disease control — remains debated. Some trials continue until progression; others cap at two years of immunotherapy.
• Sequencing after progression: Options for subsequent line therapy can be limited if a patient has received multiple immune checkpoint inhibitors upfront. Biomarker-based salvage strategies are an active area of investigation.

Likely Impact on Clinical Practice and Patient Outcomes

As combination regimens become more common, several outcomes are anticipated:

• Improved overall response rates and median survival across diverse patient populations, particularly those with PD-L1 expression below 50%.
• Greater need for multidisciplinary care — with closer involvement of pulmonology, pathology, and supportive oncology teams to manage complex irAEs.
• Pressure on rapid molecular testing: To guide combination selection, comprehensive profiling (PD-L1, TMB, and other candidate biomarkers) will need to be completed within days of diagnosis.
• Expansion of clinical trial enrollment for underserved subgroups (e.g., older adults, patients with autoimmune history) to gather real-world evidence on safety and efficacy.

What to Watch Next

The next few years will likely bring clearer guidance on which combination works best for which patient. Watch for these developments:

• Head-to-head trials comparing different combination platforms (e.g., chemo-immunotherapy vs. dual checkpoint alone) to establish hierarchy.
• Novel targets: Combinations incorporating LAG-3, TIM-3, or bispecific antibodies may enter first-line space.
• Biomarker refinement: Integration of liquid biopsy and immune profiling to predict response and toxicity before treatment starts.
• Adaptive trial designs that allow mid-course switches or de-escalation based on early response.
• Longer follow-up of existing registration trials to confirm whether combination benefits persist beyond five years.